{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:57:20Z","timestamp":1790708240150,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009455","name":"West Virginia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["CTN-0051"],"award-info":[{"award-number":["CTN-0051"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jad.2021.10.018","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T18:49:31Z","timestamp":1634582971000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale"],"prefix":"10.1016","volume":"297","author":[{"given":"Kesheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"DiChiacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Winstanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ubolrat Piamjariyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.10.018_bib0001","series-title":"Diagnostic and Statistical Manual of Mental disorders: DSM-5","year":"2013"},{"key":"10.1016\/j.jad.2021.10.018_bib0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpsychires.2015.06.003","article-title":"Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant","volume":"68","author":"Ballard","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.10.018_bib0003","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4088\/JCP.10m06673","article-title":"Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"73","author":"Blanco","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"10182","key":"10.1016\/j.jad.2021.10.018_bib0004","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2021.10.018_bib0005","series-title":"Principles of Addiction Medicine. 3. Chevy","first-page":"1277","article-title":"Co-occurring addictive and affective disorders","author":"Brady","year":"2003"},{"key":"10.1016\/j.jad.2021.10.018_bib0006","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.3389\/adar.2021.10009","article-title":"Mechanisms underlying the anti-suicidal treatment potential of buprenorphine","volume":"11","author":"Cameron","year":"2021","journal-title":"Adv. Drug Alcohol Res."},{"issue":"3","key":"10.1016\/j.jad.2021.10.018_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000506879","article-title":"The Hamilton rating scales for depression: a critical review of clinimetric properties of different versions","volume":"89","author":"Carrozzino","year":"2020","journal-title":"Psychother. Psychosom."},{"issue":"12","key":"10.1016\/j.jad.2021.10.018_bib0008","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1089\/pho.2018.4490","article-title":"Transcranial photobiomodulation for the treatment of major depressive disorder. The ELATED-2 pilot trial","volume":"36","author":"Cassano","year":"2018","journal-title":"Photomed. Laser .Surg."},{"issue":"11","key":"10.1016\/j.jad.2021.10.018_bib0009","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.biopsych.2019.05.021","article-title":"The Kappa opioid receptor is associated with naltrexone-induced reduction of drinking and craving","volume":"86","author":"de Laat","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.10.018_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2019.08.020","article-title":"Transcranial direct current stimulation for the treatment of generalized anxiety disorder: a randomized clinical trial","volume":"259","author":"de Lima","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2021.10.018_bib0011","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eurpsy.2004.09.002","article-title":"Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence","volume":"19","author":"Dean","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2021.10.018_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1139\/jpn.0605","article-title":"Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence","volume":"31","author":"Dean","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jad.2021.10.018_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jad.2014.08.023","article-title":"Therapist-rated outcomes in a randomized clinical trial comparing cognitive behavioral therapy and psychodynamic therapy for major depression","volume":"170","author":"Driessen","year":"2015","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2021.10.018_bib0014","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as djunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2021.10.018_bib0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.jad.2021.10.018_bib0016","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder","volume":"48","author":"Frank","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2021.10.018_bib0017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.jad.2021.10.018_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpsychires.2017.02.026","article-title":"Depression care among adults with co-occurring major depressive episodes and substance use disorders in the United States","volume":"91","author":"Han","year":"2017","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.jad.2021.10.018_bib0019","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.10.018_bib0020","article-title":"Psychological interventions for co-occurring depression and substance use disorders","volume":"11","author":"Hides","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2021.10.018_bib0021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0376-8716(81)90084-3","article-title":"Aversive effects of naltrexone in subjects not dependent on opiates","volume":"8","author":"Hollister","year":"1981","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jad.2021.10.018_bib0022","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/add.13795","article-title":"Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12","volume":"112","author":"Hsu","year":"2017","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jad.2021.10.018_bib0023","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41386-018-0252-0","article-title":"Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients","volume":"44","author":"Huhn","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jad.2021.10.018_bib0024","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1455072520910551","article-title":"Substance use disorder patients\u2019 expectations in transition from treatment to post-discharge period","volume":"37","author":"Johannessen","year":"2020","journal-title":"Nordic Stud. Alcohol Drugs"},{"key":"10.1016\/j.jad.2021.10.018_bib0025","first-page":"1","article-title":"Adverse childhood experience patterns, major depressive disorder, and substance use disorder in older adults","volume":"26","author":"Kim","year":"2019","journal-title":"Aging Ment. Health"},{"key":"10.1016\/j.jad.2021.10.018_bib0026","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","article-title":"Naltrexone for heroin dependence treatment in St. Petersburg","volume":"26","author":"Krupitsky","year":"2004","journal-title":"Russia. J. Subst. Abuse Treat."},{"issue":"9","key":"10.1016\/j.jad.2021.10.018_bib0027","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/0269881117719261","article-title":"Effect of desvenlafaxine 50mg and 100mg on energy and lassitude in patients with major depressive disorder: a pooled analysis","volume":"31","author":"Lam","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.10.018_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.copsyc.2018.12.020","article-title":"Comorbidity of opioid-related and anxiety-related symptoms and disorders","volume":"30","author":"Langdon","year":"2019","journal-title":"Curr. Opin. Psychol."},{"issue":"10118","key":"10.1016\/j.jad.2021.10.018_bib0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2021.10.018_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT): study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"J. Contemp. Clin. Trials"},{"issue":"4","key":"10.1016\/j.jad.2021.10.018_bib0031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/15504263.2019.1656353","article-title":"Outcome of patients with high depressive symptoms on admission to methadone maintenance treatment","volume":"15","author":"Malik","year":"2019","journal-title":"J. Dual. Diagn."},{"key":"10.1016\/j.jad.2021.10.018_bib0032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2016.12.001","article-title":"Barriers and facilitators to successful transition from long-term residential substance abuse treatment","volume":"74","author":"Manuel","year":"2017","journal-title":"J Subst. Abuse Treat."},{"key":"10.1016\/j.jad.2021.10.018_bib0033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2017.07.006","article-title":"Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: study protocol and methods","volume":"60","author":"McHugh","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jad.2021.10.018_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0376-8716(97)01348-3","article-title":"Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts","volume":"45","author":"Miotto","year":"1997","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jad.2021.10.018_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2021.10.018_bib0036","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","article-title":"The association between naltrexone treatment and symptoms of depression in opioid-dependent patients","volume":"37","author":"Mysels","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jad.2021.10.018_bib0037","unstructured":"National Institute of Mental Health (NIMH), 2017. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression. (Accessed 10 September 2021)."},{"key":"10.1016\/j.jad.2021.10.018_bib0038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of an effectiveness trial: a comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemp. Clin Trials"},{"issue":"3","key":"10.1016\/j.jad.2021.10.018_bib0039","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/15504263.2019.1619007","article-title":"Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: a systematic review and meta-analysis","volume":"15","author":"Onyeka","year":"2019","journal-title":"J. Dual. Diagn."},{"issue":"12","key":"10.1016\/j.jad.2021.10.018_bib0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot\u2019alora","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2021.10.018_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008373","article-title":"Pharmacological treatment for depression during opioid agonist treatment for opioid dependence","author":"Pani","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.jad.2021.10.018_bib0042","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","article-title":"A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression","volume":"23","author":"Park","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2021.10.018_bib0043","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/da.23029","article-title":"Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder","volume":"37","author":"Perlis","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2021.10.018_bib0044","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2004.02.003","article-title":"A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence","volume":"75","author":"Rea","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.jad.2021.10.018_bib0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-015-4195-4","article-title":"A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression","volume":"233","author":"Richards","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.jad.2021.10.018_bib0046","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamapsychiatry.2019.3867","article-title":"Cortical connectivity moderators of antidepressant vs placebo treatment response in major depressive disorder: secondary analysis of a randomized clinical trial","volume":"77","author":"Rolle","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2021.10.018_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","article-title":"Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: a multivariable mendelian randomization analysis","volume":"78","author":"Rosoff","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2021.10.018_bib0048","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3390\/ijms19082410","article-title":"The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review","volume":"19","author":"Serafini","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jad.2021.10.018_bib0049","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5958\/2394-2061.2019.00030.2","article-title":"Study of sociodemographic correlates, anxiety, and depression among opioid dependents admitted in treatment centres in Sikkim, India","volume":"10","author":"Sharma","year":"2019","journal-title":"Open J. Psychiatry Allied Sci."},{"issue":"20","key":"10.1016\/j.jad.2021.10.018_bib0050","doi-asserted-by":"crossref","first-page":"e15425","DOI":"10.1097\/MD.0000000000015425","article-title":"Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review","volume":"98","author":"Stoicea","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jad.2021.10.018_bib0051","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55)","year":"2020"},{"key":"10.1016\/j.jad.2021.10.018_bib0052","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.drugalcdep.2004.12.001","article-title":"Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking","volume":"78","author":"Teesson","year":"2005","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.jad.2021.10.018_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2010.12.007","article-title":"Reliability of the Hamilton rating scale for depression: a meta-analysis over a period of 49 years","volume":"189","author":"Trajkovi\u0107","year":"2011","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.jad.2021.10.018_bib0054","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11920-014-0544-y","article-title":"Anxiety and substance use disorders: co-occurrence and clinical issues","volume":"17","author":"Vorspan","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2021.10.018_bib0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/NDT.S199245","article-title":"Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)","volume":"15","author":"Zajecka","year":"2019","journal-title":"Neuropsychiatr Dis. Treat."},{"issue":"2","key":"10.1016\/j.jad.2021.10.018_bib0056","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the hamilton depression rating scale","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721010922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721010922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:04:34Z","timestamp":1759025074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721010922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"alternative-id":["S0165032721010922"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.10.018","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}